Can UT Health San Antonio’s GRK2 inhibitor reduce opioid use in burn trauma care?
Can UT Health San Antonio’s GRK2-targeted therapy reduce opioid use and scarring in burn trauma? Find out what’s next for this emerging dual-action approach.
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.